Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04349631 · ClinicalTrials.gov registry record · Phase 2
A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19
A Phase 2 study, sponsored by Hope Biosciences Research Foundation.
- Completed
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT04349631 is a Phase 2 study that has completed, run by Hope Biosciences Research Foundation. The registered enrollment target is 51 participants.
The verdict
NCT04349631, a Phase 2 study, has completed, sponsored by Hope Biosciences Research Foundation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19. The study purpose is to evaluate the safety and efficacy of five IV infusions of HB-adMSCs in subjects with no signs of COVID-19.
Interventions
- BIOLOGICAL HB-adMSCs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2020-04-20 |
| Est. Completion | 2020-11-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04349631
The ClinicalTrials.gov registry entry for NCT04349631 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hope Biosciences Research Foundation, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HB-adMSCs is the first listed.
NCT04349631 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04349631 about?
NCT04349631 is a clinical study titled "A Clinical Trial to Determine the Safety and Efficacy of HB-adMSCs to Provide Protection Against COVID-19". Hope Biosciences is conducting a research study of an investigational product called autologous adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19. The study purpose is to evaluate the safety and efficacy of five IV infusions of HB-adMSCs in ...
What is the current status of trial NCT04349631?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2020-04-20. Estimated completion is 2020-11-25.
What interventions are being tested in trial NCT04349631?
The interventions under investigation include: HB-adMSCs (BIOLOGICAL).
Who is sponsoring clinical trial NCT04349631?
This trial is sponsored by Hope Biosciences Research Foundation, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.